HealthcareServices

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Forecast 2025–2034: Where Businesses Should Invest Next

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Between 2025 And 2029?

The sodium glucose cotransporter 2 (sglt2) inhibitors market has experienced robust expansion over recent years. This market is projected to expand from $10.17 billion in 2024 to $10.96 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 7.8%. Historically, this growth has been driven by factors such as initial successes in clinical trials, increasing numbers of regulatory approvals, rising rates of diabetes diagnoses, and a growing need for new diabetes therapies.

The market for sodium glucose cotransporter 2 (SGLT2) inhibitors is projected to experience substantial expansion in the coming years. This market is forecast to reach $15.09 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.3%. The anticipated growth during this period stems from factors such as the increasing prevalence of diabetes, higher obesity rates, enhanced understanding of diabetes management, and broader uses in treating heart and kidney conditions. Key trends foreseen for the forecast duration involve the incorporation of combination therapies, tailored medicine strategies, advancements in technology, and conventional drug development processes.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

Which Drivers Are Shaping The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry’s Market Share?

The expanding occurrence of diabetes is anticipated to boost the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. Diabetes involves a collection of metabolic conditions marked by elevated blood sugar levels stemming from deficiencies in insulin production, its action, or both. The rise in diabetes cases can be linked to aspects like urbanization, stress, environmental contaminants, and restricted access to healthcare facilities. Sodium glucose cotransporter 2 (SGLT2) inhibitors are utilized in diabetes management to reduce blood glucose levels by preventing glucose reabsorption in the kidneys, leading to its elimination via urine. These inhibitors also provide cardiovascular and renal advantages, making them a crucial option for managing diabetes and its associated complications. For instance, in December 2023, the Australian Bureau of Statistics reported that in 2022, 5.3% of Australians, equivalent to about 1.3 million individuals, had been diagnosed with diabetes, with rates being comparable between males (5.8%) and females (4.9%). The prevalence of diabetes has been progressively increasing, showing a significant rise with age, reaching 18.7% among those aged 75 and older. Type 2 diabetes is the most prevalent form, making up 87.6% of cases. Factors such as being born overseas, residing in socio-economically disadvantaged areas, and having a disability are linked to higher diabetes rates. Therefore, the growing prevalence of diabetes is stimulating the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.

What Are The Major Segment Types Covered In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

The sodium glucose cotransporter 2 (sglt2) inhibitorsmarket covered in this report is segmented –

1) By Type: Invokana; Jardiance; Farxiga Or Forxiga; Suglat

2) By Route Of Administration: Oral Route; Other Route Of Administration

3) By End User: Hospitals; Homecare Settings; Clinics

Subsegments:

1) By Invokana: Generic Invokana (Canagliflozin); Branded Invokana

2) By Jardiance: Generic Jardiance (Empagliflozin); Branded Jardiance

3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin); Branded Farxiga

4) By Suglat: Suglat (Sotagliflozin) For Diabetes; Suglat (Sotagliflozin) For Heart Failure

What Are The Major Trends Driving The Growth Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

Major companies operating within the sodium glucose cotransporter 2 (SGLT2) inhibitor market are prioritizing the development of dual inhibitor therapeutic solutions to enhance patient outcomes and efficiently manage blood sugar levels. Dual inhibitor therapeutic solutions denote treatments that simultaneously target two distinct sodium-glucose cotransporters, SGLT1 and SGLT2, to achieve greater efficacy in addressing conditions like heart failure and diabetes. For example, in May 2023, Lexicon Pharmaceuticals Inc., a US-based biopharmaceutical company, received authorization from the Food and Drug Administration (FDA) for sotagliflozin, a specific treatment for heart failure. This innovative, first-in-class dual inhibitor of sodium-glucose cotransporters 1 and 2 is formulated as a once-daily tablet, designed to reduce cardiovascular death, hospitalizations for heart failure, and urgent heart failure visits among adults afflicted with heart failure, type 2 diabetes, chronic kidney disease, and other associated cardiovascular risk factors. Its benefits encompass a reduction in renal glucose and sodium reabsorption, which leads to a decrease in both preload and afterload, as well as diminished sympathetic activity.

Who Are The Key Multinational Companies Dominating The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp

Browse Through More Reports Similar to the Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market 2025, By The Business Research Company

Sodium Cocoyl Isethionate Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sodium-cocoyl-isethionate-global-market-report

Sodium Reduction Ingredients Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sodium-reduction-ingredients-global-market-report

Sodium Lauryl Ether Sulfate Sles Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sodium-lauryl-ether-sulfate-sles-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795